What qualifies IBSA is research, innovation and the desire to explore new markets and bring its products to as many countries in the world as possible. This approach is the reason for the success of the Swiss Company, which at the beginning of 2021, launched a new product on two European markets.
The product in question is IALUSET HL, a topical preparation containing Hyaluronic Acid.
Let’s take a closer look: IALUSET HL is a topical product meant for the medical treatment area. The novelty of this product lies in its innovative technology, known as NAHYCO Hybrid Technology, which not only makes it possible for the tissues to get a greater concentration of Hyaluronic Acid (HA), but also maintain an adequate state of hydration.
This process, which IBSA has patented and developed in its R&D facilities in conjunction with the University of Naples, is based on the use of an innovative thermal system that does away with the need to use chemical reagents, to create hybrid cooperative complexes of high- and low-molecular-weight hyaluronic acid.
IALUSET HL is the first medical treatment product with NAHYCO technology. In early 2021, the product was launched on the Hungarian and French markets, but that is not all: IALUSET HL is, in actual fact, considered a strategic door-opener for many international markets.